Pipeline

March 15, 2020

Company	Drug/Device	Medical Condition	Status
Debiopharm	Debio 0123	refractory solid tumors that have recurred or progressed following prior platinum-based chemotherapy and for which no standard treatment is available	initiation of phase 1 trial
FSD Pharma	Ultra Micro-Plmitolylethanolamide (PEA)	inflammatory conditions	initiation of phase 1 trial
Virometix	V-306 vaccine	respiratory syncytial virus	initiation of phase 1 trial
Actinium Pharma	Actimab-A CLAG-M combination	relapsed or refractory acute myeloid leukemia	first patient treated in third and final cohort of phase 1 trial
Innate Pharma AstraZeneca	IPH5201 alone and in combination with durvalumab with or without oleclumab	advanced solid tumors	first patient dosed in phase 1 trial
Medivir AB	MIV-818	advanced liver cancer	first patient dosed in phase 1b study
InMed Pharma	INM-755	epidermolysis bullosa and potentially other dermatological diseases	patient enrollment complete in phase 1 study
Albireo	elobixibat	nonalcoholic steatohepatitis and nonalcoholic fatty liver disease	patient enrollment complete in phase 2 study
Tenax Therapeutics	levosimendan	pulmonary hypertension and heart failure with preserved ejection fraction	patient enrollment complete in phase 2 study
Palvella Therapeutics	PTX-022 (QTORIN 3.9% rapamycin anhydrous gel)	Pachyonychia Congenita	patient enrollment complete in phase 2/3 study
QED Therapeutics	infigratinib	adjuvant treatment of invasive urothelial carcinoma	first patient dosed in phase 3 trial
ARVOBIO	AVR-RD-04 gene therapy	cystinosis	Orphan Drug designation granted by FDA
TG Therapeutics	umbralisib	follicular lymphoma	Orphan Drug designation granted by FDA
Spero Therapeutics	oral SPR720	nontuberculous mycobacterial infection	Orphan Drug designation granted by FDA
Janssen	JNJ-6372	metastatic non-small cell lung cancer with EGFR Exon 20 insertion mutations where the disease has progressed while the patient is on or after receiving platinum-based chemotherapy	Breakthrough Therapy designation granted by FDA
Neuronetics	NeuroStar Advanced Therapy System	bipolar depression	Breakthrough Device designation granted by FDA
Aerin Medical	RhinAer Stylus	chronic rhinitis	approved by the FDA
Allergan	Durysta (bimatoprost implant)	open-angle glaucoma or ocular hypertension	approved by the FDA
AltaThera Pharmaceuticals	Sotalol IV	atrial fibrillation	new indications approved by the FDA
Boehringer-Ingelheim	Ofev (nintedanib)	chronic fibrosing interstitial lung diseases with a progressive phenotype	approved by the FDA
Bristol-Myers Squibb	Opdivo (nivolumab) and Yervoy (ipilimumab)	hepatocellular carcinoma which has been previously treated with Bayer’s Nexavar (sorafenib)	approved by the FDA
Recordati	Isturisa (osilodrostat)	Cushing's disease when pituitary surgery is not an option or has not been curative	approved by the FDA